New drug cizutamig tested for rare autoimmune disease
NCT ID NCT07158996
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This early-phase study will test a new drug, cizutamig, in 10 adults with systemic sclerosis, a condition that causes skin hardening and organ damage. The main goal is to check if the drug is safe and tolerable, while also looking at how the body processes it and whether it shows any signs of helping control the disease. Participants must have a certain level of skin thickening and have not responded well to other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.